% | $
Quotes you view appear here for quick access.

Actavis plc Message Board

oilpooldeeps 3 posts  |  Last Activity: Apr 10, 2015 7:14 AM Member since: May 7, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • oilpooldeeps oilpooldeeps Apr 10, 2015 7:14 AM Flag

    You aren't in China, and you don't know anything. But feel free to grace us with your insightful and and thought-provoking posts on BABA any old time. Every message board needs a clown to entertain the rest of the board. Do you wear those long floppy hats with jingle bells on the end when you get on the internet? Maybe to help you get in "the zone" before you post???

  • Reply to

    It was Goldman this time , it looks like ....

    by oilpooldeeps Apr 3, 2015 9:37 AM
    oilpooldeeps oilpooldeeps Apr 3, 2015 12:25 PM Flag

    Update: I guess this is nothing new. The list format is new but the targets and some of the ratings are not. Celgene has the same target as it has had from them. It looks more to be the case that Goldman is still waiting for their price target of $70 to materialize more than a year after making the call. That means 4 sets of earnings have been released since they first made it, with nothing yet having surfaced to justify their reasoning. It goes without saying they are shorting.

  • They put out list of top stocks for the next 12 months, and worst stocks , about 25-30 for each list. Celgene was listed in position # 1 as the very worst to own , with a projected share price decline of 35%. Lists only, reasons not given. Either they think that Revlimid is in danger of being outclassed by a superior new drug, or they think a patent problem is worse than expected, or they think the pricing is vulnerable. I have no idea. Don't know what to think about that. I do think they are the most accurate forecasters around, but still they are not always right obviously, and there is no one else this pessimistic, or even close. Gilead is on the list as well, about # 20 or so. Does anyone know their rationale for this???

307.51-1.65(-0.53%)10:54 AMEDT